

# Red Flags Raising Suspicion of Eosinophilic Granulomatosis with Polyangiitis: An EGPAware European Consensus

GSK provided funding towards the EGPAware consensus and this infographic, and editorial input in the latter. The information provided in this infographic has been peer-reviewed as part of Hellmich et al.<sup>1</sup> EMJ. 2026;11[1]:34-35. <https://doi.org/10.33590/emj/ABOL8230>

## Introduction

EGPA is a rare, multisystemic disease, often including asthma, that requires MDT management and expert diagnostic evaluation



Diagnosis and treatment of EGPA are often delayed, which highlights the need for **early identification**

## Study Design

EGPAware is the first large European Delphi study, aiming to establish a multidisciplinary consensus of clinical suspicion criteria for EGPA.



Red flags were ranked by panellists based on **CR** and on **FO**.

### Panellists:



**53** EGPA-treating physicians from **17** European countries.




Most panellists were rheumatologists or pulmonologists, with 50% having >15 years of experience in EGPA-patient management.

Consensus was reached for 25 red flags for EGPA suspicion\*



## Highest Ranked Red Flags



Ranking of 10 most relevant red flags based on clinical relevance and frequency of observation (inverse balanced mean: 1 least relevant; 10 most relevant)

<sup>†</sup>Regardless of the diagnostic method, be it clinical, laboratory (e.g., proBNP), or imaging (e.g., echo, MRI)

<sup>‡</sup>Not explained by another cause

## Key Takeaways

The most clinically relevant signs were:



The most frequently observed signs were:



Clinician awareness of these suspicion criteria will enhance awareness, improve referral rates, and reduce diagnostic delays

\*This figure contains the 25 red flags that achieved consensus among panellists. The signs highlighted in bold correspond to the 12 most pertinent red flags based both on CR and on FO.  
<sup>†</sup>Not explained by another cause.